Amlitelimab (Anti-TNFSF4 / OX40L / CD252) CD markers | Read Reviews & Product Use Citations

Amlitelimab (Anti-TNFSF4 / OX40L / CD252) is a nondepleting IgG4 human anti-OX40L monoclonal antibody with the potential to treat atopic dermatitis. MW: 145.94 kD.

Quality Control

Batch: A276201 Purity: 99% Protein concentration: 5.67mg/ml Endotoxin Level: ＜1EU/mg

Cited in Nature Medicine for its top-tier quality
COA
SDS
Datasheet

99

Featured Inhibitors	Y-27632 Dihydrochloride SB431542 CHIR-99021 (Laduviglusib) RMC-7977 RMC-6236 (Daraxonrasib) MRTX1133 MG132 Z-VAD-FMK VT3989 IAG933

Specificity

Name	Citation	CD38	CD45	CD39	CD88	CD73	Others
RBN013209	0	++
MK-0159	0	+++
CD38 inhibitor 1 (compound 78c)	7	+++
AB680	1					++++
NQ301	1		+				TXA2 receptor
SodiuM Metatungstate	3			++
PMX-53	3				✔
LY-3475070	2					✔

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description	Amlitelimab (Anti-TNFSF4 / OX40L / CD252) is a nondepleting IgG4 human anti-OX40L monoclonal antibody with the potential to treat atopic dermatitis. MW: 145.94 kD.
References	[1] https://pubmed.ncbi.nlm.nih.gov/35092305/

Product Details

CAS No.	2378692-15-8
Molecular Weight	145.94
Isotype	Human IgG4SP
Source	CHO
Purification	AKTA
Sterility	0.2 μM filtered
Formulation	100 mM Pro-Ac, 20mM Arg, pH5.0
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05769777	ACTIVE_NOT_RECRUITING	Drug: Amlitelimab	Dermatitis Atopic	Sanofi	2023-04-03	PHASE2
NCT05492578	ACTIVE_NOT_RECRUITING	Drug: Amlitelimab\|Drug: Topical corticosteroids\|Drug: Topica	Dermatitis Atopic	Sanofi	2022-08-22	PHASE2; PHASE3
NCT06241118	ACTIVE_NOT_RECRUITING	Drug: Amlitelimab\|Drug: Placebo\|Drug: Topical corticosteroid	Dermatitis Atopic	Sanofi	2024-02-29	PHASE3
NCT06812988	ACTIVE_NOT_RECRUITING	Drug: Brivekimig\|Drug: Placebo	Type 1 Diabetes Mellitus	Sanofi	2025-02-28	PHASE2
NCT06195072	RECRUITING	Drug: Amlitelimab\|Drug: BI 1015550 (Nerandomilast)\|Drug: Pla	Interstitial Lung Disease Due to Systemic Disease; Scleroderma	Scleroderma Research Foundation, Inc.	2024-04-15	PHASE2
NCT06033833	ACTIVE_NOT_RECRUITING	Drug: Amlitelimab\|Drug: Placebo	Asthma	Sanofi	2023-09-05	PHASE2

(data from https://clinicaltrials.gov, updated on 2026-04-23)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.